As you go through the clinical development process, unforeseen risks and hurdles can cost you significant time and money. Excelya offers all necessary clinical operations & project management capabilities to ensure smooth execution of clinical trials, from phase I to IV, to simplify your journey to market. We offer regulatory expertise, medical writing and communications and data operations to see you through to the post-market phase.
Our Clinical Operations team works closely with local and international Key Opinion Leaders and with our pivotal operational departments, such as Medical Writing, Vendor Management, Regulatory Affairs, Data Management and Pharmacovigilance to quickly deliver trials that meet the highest standards. Our highly flexible and customer-centric approach ensures constant communication with our clients to make sure your trial is done right.
Our comprehensive central services solution aligns all of your vendors to work together towards your objective. Our Contributors find simplicity within complexity.
We leverage a functional and organizational “Deliverables” model implemented in Trial Operations called Vendor Management and Oversight (VMO). This model deploys dedicated specialized Contributors for each centralized activity of the study covered by VMO.
These activities include:
Features of our VMO contributors
CROSS-DISCIPLINARY: Have cross-disciplinary view across multiple therapeutic areas and are part of the Study team.
SPECIALIZED: Service experts specialized in managing their activities across studies.
FLEXIBLE: Flexible working patterns to cover multiple time zones.
COVERAGE: Are typically involved in several studies.
TASK-ORIENTED: Work based on a specific list of tasks which defines their scope.
EXCELYATES: Are Excelya employees and we will indemnify clients against co-employment risk.
Decreased costs by 16%
We assessed all vendors and scope of work to harmonize resources and reduce study costs by 16%.
Optimized time by 10%, twice
In the first 18 months, we optimized time spent by 10%.
Another 18 months later, we had optimized by another 10%.
